SpyGlass Pharma, Inc. Common Stock (SGP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for SpyGlass Pharma, Inc. Common Stock in 2026. The next earnings report is expected on December 2, 2026.
Next earnings date
02 Dec 2026
In 104 days
EPS estimate
-0.62
Revenue estimate
0
Past earnings
Latest earnings analysis
SpyGlass Pharma missed consensus estimates in its latest earnings report, with EPS of $-0.59 versus an estimate of $-0.5144, while revenue met estimates at $0. No prior report is available for comparison.
No dividend history available.
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
SpyGlass Pharma, Inc. Common Stock (SGP) is scheduled to report earnings on December 2, 2026.
SpyGlass Pharma, Inc. Common Stock (SGP) last reported earnings on August 6, 2026.
SpyGlass Pharma, Inc. Common Stock (SGP) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.